RMD

SEC source: 0000943819-25-000084 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000061 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,020

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000061 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 467,792

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $275.27 - $279.57. The price reported above reflects the weighted average sale price.

SEC source: 0000943819-25-000061 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 475,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

SEC source: 0000943819-25-000052 · form4.xml · derivative · entry 3

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,000

Underlying: ResMed Common Stock · 2,000 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000052 · form4.xml · nonDerivative · entry 2

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,745

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000052 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0001127602-25-021161 · form4.xml · nonDerivative · entry 1

Mowad-Nassar Nicole · CIK 0002084190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241

F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the first anniversary of the grant date.

SEC source: 0001127602-25-020653 · form4.xml · derivative · entry 3

Hernandez John · CIK 0001890555 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: ResMed Common Stock · 2,575 shares

Expires 2030-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents the date options become exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date.

SEC source: 0001127602-25-020653 · form4.xml · nonDerivative · entry 2

Hernandez John · CIK 0001890555 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,045

F1 · price: This transaction was executed in multiple trades at prices ranging from $286.90 - $287.24. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-25-020653 · form4.xml · nonDerivative · entry 1

Hernandez John · CIK 0001890555 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000943819-25-000041 · form4.xml · nonDerivative · entry 1

Leong Justin · CIK 0001825782 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,180

F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

SEC source: 0000943819-25-000040 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,745

F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

SEC source: 0000943819-25-000039 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,792

F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest1/3 each year on the anniversary of the grant.

SEC source: 0001127602-25-020652 · form4.xml · nonDerivative · entry 1

Rider Michael J · CIK 0001982205 · Global General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,427

F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

SEC source: 0000943819-25-000038 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,029

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000038 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,503

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $277.76 - $282.66. The price reported above reflects the weighted average sale price.

SEC source: 0000943819-25-000038 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

SEC source: 0000943819-25-000030 · form4.xml · nonDerivative · entry 1

Rider Michael J · CIK 0001982205 · Global General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,486

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

SEC source: 0000943819-25-000032 · form4.xml · derivative · entry 3

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,000

Underlying: ResMed Common Stock · 2,000 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000032 · form4.xml · nonDerivative · entry 2

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,283

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000032 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000027 · form4.xml · derivative · entry 3

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,038

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000027 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,503

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $255.6 - $258.22. The price reported above reflects the weighted average sale price.

SEC source: 0000943819-25-000027 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

SEC source: 0000943819-25-000026 · form4.xml · nonDerivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,273

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024

SEC source: 0000943819-25-000025 · form4.xml · derivative · entry 5

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,000

Underlying: ResMed Common Stock · 917 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000025 · form4.xml · derivative · entry 4

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,917

Underlying: ResMed Common Stock · 1,966 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 3

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,283

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 2

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0000943819-25-000024 · form4.xml · nonDerivative · entry 1

Rider Michael J · CIK 0001982205 · Global General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,536

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

SEC source: 0000943819-25-000019 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,047

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0000943819-25-000019 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,503

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $248.57 - $252.31. The price reported above reflects the weighted average sale price.

SEC source: 0000943819-25-000019 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

SEC source: 0000943819-25-000013 · form4.xml · nonDerivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,218

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024

SEC source: 0000943819-25-000011 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,283

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

SEC source: 0001127602-25-016359 · form4.xml · nonDerivative · entry 2

Rider Michael J · CIK 0001982205 · Global General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,603

F3 · shares: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 06/01/2023.

SEC source: 0001127602-25-016359 · form4.xml · nonDerivative · entry 1

Rider Michael J · CIK 0001982205 · Global General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,870

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

F2 · balance_after: Includes 64.6438 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan.

SEC source: 0001127602-25-015607 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,283

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

F2 · balance_after: Includes 62.6994 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan.

SEC source: 0001127602-25-015264 · form4.xml · nonDerivative · entry 1

De Witte Jan · CIK 0001776929 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,806

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 3, 2025.

SEC source: 0001127602-25-013743 · form4.xml · nonDerivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,218

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024

SEC source: 0001127602-25-013796 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,056

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0001127602-25-013796 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,503

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $241.50 - $245.09. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-25-013796 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · balance_after: Includes 30.3711 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan.

SEC source: 0001127602-25-011925 · form4.xml · nonDerivative · entry 1

Sandercock Brett · CIK 0001346064 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,864

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024.

SEC source: 0001127602-25-011839 · form4.xml · derivative · entry 4

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,065

Underlying: ResMed Common Stock · 8,009 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year.

SEC source: 0001127602-25-011839 · form4.xml · nonDerivative · entry 2

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,472

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $200.18 - $218.54. The price reported above reflects the weighted average sale price.

SEC source: 0001127602-25-011839 · form4.xml · nonDerivative · entry 1

Farrell Michael J. · CIK 0001485164 · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

SEC source: 0001127602-25-011625 · form4.xml · nonDerivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,218

F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024